Cargando…
A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
PURPOSE: Given the high prevalence of diabetes (D), several animal models have been analyzed. In the literature, most of the animal models have studied severe D. However, in clinical practice, most patients have moderate disease. Therefore, the present study aimed to describe a moderate D condition....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412997/ https://www.ncbi.nlm.nih.gov/pubmed/32813772 http://dx.doi.org/10.1590/s0102-865020200070000004 |
_version_ | 1783568718254571520 |
---|---|
author | Camargo, Cristina Pires Weschenfelder, Rafael Hori Nagamine da Fonseca, Guilherme Moreira Sousa, Alexandre Agostinho da Cruz Gemperli, Rolf |
author_facet | Camargo, Cristina Pires Weschenfelder, Rafael Hori Nagamine da Fonseca, Guilherme Moreira Sousa, Alexandre Agostinho da Cruz Gemperli, Rolf |
author_sort | Camargo, Cristina Pires |
collection | PubMed |
description | PURPOSE: Given the high prevalence of diabetes (D), several animal models have been analyzed. In the literature, most of the animal models have studied severe D. However, in clinical practice, most patients have moderate disease. Therefore, the present study aimed to describe a moderate D condition. METHODS: We analyzed 20 Wistar rats, age eight-weeks, weight between 200g-250g. All animals received an intravenous injection of Streptozotocin (55mg/kg weight). On the 15th day after D induction, the animals were divided into two groups: Group I – animals receiving a single daily dose of fast-acting insulin (FAIG) NPH (1UI,SC) for partial glycemic control, and Group II - animals receiving slow-acting insulin(SAIG) twice a week. We measured glycemia, weight, and adverse events every week during two months. RESULTS: Of the total of animals analyzed in the study, three animals died in the FAIG and two animals died in the SAIG. Regarding the glycemic level, results were 339.5 ± 125.4mg/dL (95CI 302.3402 to 376.6842) in the FAIG, and 367.8 ± 66.1mg/dL (95IC 333.7607 to 401.8978) in the SAIG. There was no difference between groups as to weight during the study. CONCLUSION: The use of slow-acting-insulin is not inferior to the use of fast-acting-insulin in the management of partially insulin-controlled moderate diabetes in rats. |
format | Online Article Text |
id | pubmed-7412997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia |
record_format | MEDLINE/PubMed |
spelling | pubmed-74129972020-08-25 A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode Camargo, Cristina Pires Weschenfelder, Rafael Hori Nagamine da Fonseca, Guilherme Moreira Sousa, Alexandre Agostinho da Cruz Gemperli, Rolf Acta Cir Bras Original Article PURPOSE: Given the high prevalence of diabetes (D), several animal models have been analyzed. In the literature, most of the animal models have studied severe D. However, in clinical practice, most patients have moderate disease. Therefore, the present study aimed to describe a moderate D condition. METHODS: We analyzed 20 Wistar rats, age eight-weeks, weight between 200g-250g. All animals received an intravenous injection of Streptozotocin (55mg/kg weight). On the 15th day after D induction, the animals were divided into two groups: Group I – animals receiving a single daily dose of fast-acting insulin (FAIG) NPH (1UI,SC) for partial glycemic control, and Group II - animals receiving slow-acting insulin(SAIG) twice a week. We measured glycemia, weight, and adverse events every week during two months. RESULTS: Of the total of animals analyzed in the study, three animals died in the FAIG and two animals died in the SAIG. Regarding the glycemic level, results were 339.5 ± 125.4mg/dL (95CI 302.3402 to 376.6842) in the FAIG, and 367.8 ± 66.1mg/dL (95IC 333.7607 to 401.8978) in the SAIG. There was no difference between groups as to weight during the study. CONCLUSION: The use of slow-acting-insulin is not inferior to the use of fast-acting-insulin in the management of partially insulin-controlled moderate diabetes in rats. Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2020-08-05 /pmc/articles/PMC7412997/ /pubmed/32813772 http://dx.doi.org/10.1590/s0102-865020200070000004 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Camargo, Cristina Pires Weschenfelder, Rafael Hori Nagamine da Fonseca, Guilherme Moreira Sousa, Alexandre Agostinho da Cruz Gemperli, Rolf A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode |
title | A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
|
title_full | A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
|
title_fullStr | A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
|
title_full_unstemmed | A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
|
title_short | A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode
|
title_sort | non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes mode |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412997/ https://www.ncbi.nlm.nih.gov/pubmed/32813772 http://dx.doi.org/10.1590/s0102-865020200070000004 |
work_keys_str_mv | AT camargocristinapires anoninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode AT weschenfelderrafaelhorinagamine anoninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode AT dafonsecaguilhermemoreira anoninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode AT sousaalexandreagostinhodacruz anoninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode AT gemperlirolf anoninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode AT camargocristinapires noninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode AT weschenfelderrafaelhorinagamine noninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode AT dafonsecaguilhermemoreira noninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode AT sousaalexandreagostinhodacruz noninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode AT gemperlirolf noninferioritystudytocomparedailyfastactinginsulinversustwiceaweekslowactinginsulinmoderatediabetesmode |